                         SEQUENCE LISTING

<110>  SENTMAN, Charles L.
       GRABER, David
       COOK, W. James
 
<120>  SIGNALING PLATFORMS FOR CHIMERIC ANTIGEN RECEPTOR T CELLS

<130>  1143252.003213

<140>  To be assigned
<141>  2020-01-31

<150>  62/799,924
<151>  2019-02-01

<160>  8     

<170>  PatentIn version 3.5

<210>  1
<211>  19
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  tyrosine-based activation motif (ITAM)


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  Xaa denotes Asp or Glu

<220>
<221>  misc_feature
<222>  (2)..(3)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (5)..(6)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  Xaa denotes Ile or Leu

<220>
<221>  misc_feature
<222>  (8)..(15)
<223>  Xaa denotes 6 to 8 amino acid residues, wherein the amino acid 
       can be any amino acid residue, where one or two positions can 
       be absent

<220>
<221>  misc_feature
<222>  (17)..(18)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  misc_feature
<222>  (19)..(19)
<223>  Xaa denotes Ile or Leu

<400>  1

Xaa Xaa Xaa Tyr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Tyr 
1               5                   10                  15      


Xaa Xaa Xaa 
                       


<210>  2
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  flexible polypeptide linker

<400>  2

Gly Gly Gly Gly Ser 
1               5   


<210>  3
<211>  90
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-B7H6 CAR comprising a CD28 co-stimulatory domain

<400>  3

Ala Ser Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe Pro Gly 
1               5                   10                  15      


Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala 
            20                  25                  30          


Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg 
        35                  40                  45              


Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro 
    50                  55                  60                  


Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro 
65                  70                  75                  80  


Arg Asp Phe Ala Ala Tyr Arg Ser Lys Leu 
                85                  90  


<210>  4
<211>  77
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-B7H6 CAR with a DAP10 co-stimulatory domain

<400>  4

Ala Ser Gln Thr Thr Pro Gly Glu Arg Ser Ser Leu Pro Ala Phe Tyr 
1               5                   10                  15      


Pro Gly Thr Ser Gly Ser Cys Ser Gly Cys Gly Ser Leu Ser Leu Pro 
            20                  25                  30          


Leu Leu Ala Gly Leu Val Ala Ala Asp Ala Val Ala Ser Leu Leu Ile 
        35                  40                  45              


Val Gly Ala Val Phe Leu Cys Ala Arg Pro Arg Arg Ser Pro Ala Gln 
    50                  55                  60                  


Glu Asp Gly Lys Val Tyr Ile Asn Met Pro Gly Arg Gly 
65                  70                  75          


<210>  5
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Motif 1

<400>  5

Asp Tyr Met Asn Met 
1               5   


<210>  6
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Motif 2

<400>  6

Pro Arg Arg Pro 
1               


<210>  7
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Motif 3

<400>  7

Pro Tyr Ala Pro 
1               


<210>  8
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  hDap10 NKG2D binding

<400>  8

Val Ala Ala Asp Ala 
1               5   


